Trevor Martin Janice Chen Mammoth Biosciences is a biotechnology company based in Brisbane, California[1] developing diagnostic tests using CRISPR-Cas12a and CRISPR-based therapies using its proprietary ultra-small CRISPR systems.
Several CRISPR-Cas systems identified through the company's metagenomics-based protein discovery platform, including members of the Casφ and Cas14 families of CRISPR-associated enzymes, have demonstrated potential for therapeutic genome editing in in vivo settings.
[6] The technology, which is owned under the trademark of DETECTR BOOST, has been contracted to be manufactured by Merck & Co.[7] In 2023, the company announced that it will focus on developing CRISPR-based therapies.
[9][10] Compared to Cas9, CasΦ and Cas14 may also offer less restrictive protospacer adjacent motif requirements, advantageous off-target activity, and allele-specific editing capabilities, which could broaden the range of targetable diseases in the genome.
[10][9] Mammoth previously announced partnerships with Vertex Pharmaceuticals (2021) and Bayer (2022) to research ultra-small CRISPR systems for in vivo editing.